These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 34469480)

  • 1. A broad-spectrum and highly potent human monoclonal antibody cocktail for rabies prophylaxis.
    Kim PK; Ahn JS; Kim CM; Seo JM; Keum SJ; Lee HJ; Choo MJ; Kim MS; Lee JY; Maeng KE; Shin JY; Yi KS; Osinubi MOV; Franka R; Greenberg L; Shampur M; Rupprecht CE; Lee SY
    PLoS One; 2021; 16(9):e0256779. PubMed ID: 34469480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of broad-spectrum human monoclonal antibodies for rabies post-exposure prophylaxis.
    De Benedictis P; Minola A; Rota Nodari E; Aiello R; Zecchin B; Salomoni A; Foglierini M; Agatic G; Vanzetta F; Lavenir R; Lepelletier A; Bentley E; Weiss R; Cattoli G; Capua I; Sallusto F; Wright E; Lanzavecchia A; Bourhy H; Corti D
    EMBO Mol Med; 2016 Apr; 8(4):407-21. PubMed ID: 26992832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of Recombinant Human Monoclonal Antibody Cocktail for Post-exposure Rabies Prophylaxis].
    Sun L; Liu Y; Li C; Li D; Liang M
    Bing Du Xue Bao; 2016 Jul; 32(4):399-403. PubMed ID: 29979531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SYN023, a novel humanized monoclonal antibody cocktail, for post-exposure prophylaxis of rabies.
    Chao TY; Ren S; Shen E; Moore S; Zhang SF; Chen L; Rupprecht CE; Tsao E
    PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006133. PubMed ID: 29261658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation and characterization of neutralizing human recombinant antibodies against antigenic site II of rabies virus glycoprotein.
    Sun L; Chen Z; Yu L; Wei J; Li C; Jin J; Shen X; Lv X; Tang Q; Li D; Liang M
    Appl Microbiol Biotechnol; 2012 Oct; 96(2):357-66. PubMed ID: 22678022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans.
    Müller T; Dietzschold B; Ertl H; Fooks AR; Freuling C; Fehlner-Gardiner C; Kliemt J; Meslin FX; Franka R; Rupprecht CE; Tordo N; Wanderler AI; Kieny MP
    PLoS Negl Trop Dis; 2009 Nov; 3(11):e542. PubMed ID: 19888334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants.
    Bakker AB; Marissen WE; Kramer RA; Rice AB; Weldon WC; Niezgoda M; Hanlon CA; Thijsse S; Backus HH; de Kruif J; Dietzschold B; Rupprecht CE; Goudsmit J
    J Virol; 2005 Jul; 79(14):9062-8. PubMed ID: 15994800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin.
    Goudsmit J; Marissen WE; Weldon WC; Niezgoda M; Hanlon CA; Rice AB; Kruif Jd; Dietzschold B; Bakker AB; Rupprecht CE
    J Infect Dis; 2006 Mar; 193(6):796-801. PubMed ID: 16479514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental utility of rabies virus-neutralizing human monoclonal antibodies in post-exposure prophylaxis.
    Hanlon CA; DeMattos CA; DeMattos CC; Niezgoda M; Hooper DC; Koprowski H; Notkins A; Rupprecht CE
    Vaccine; 2001 Jul; 19(28-29):3834-42. PubMed ID: 11427255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Negative effects of a disulfide bond mismatch in anti-rabies G protein single-chain antibody variable fragment FV57.
    Duan Y; Gu T; Zhang X; Jiang C; Yuan R; Li Z; Wang D; Chen X; Wu C; Chen Y; Wu Y; Kong W
    Mol Immunol; 2014 Jun; 59(2):136-41. PubMed ID: 24598312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigenic site changes in the rabies virus glycoprotein dictates functionality and neutralizing capability against divergent lyssaviruses.
    Evans JS; Selden D; Wu G; Wright E; Horton DL; Fooks AR; Banyard AC
    J Gen Virol; 2018 Feb; 99(2):169-180. PubMed ID: 29300155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cocktail of human monoclonal antibodies broadly neutralizes North American rabies virus variants as a promising candidate for rabies post-exposure prophylaxis.
    Ejemel M; Smith TG; Greenberg L; Carson WC; Lowe D; Yang Y; Jackson FR; Morgan CN; Martin BE; Kling C; Hutson CL; Gallardo-Romero N; Ellison JA; Moore S; Buzby A; Sullivan-Bolyai J; Klempner M; Wang Y
    Sci Rep; 2022 Jun; 12(1):9403. PubMed ID: 35672343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolation and Characterization of Cross-Reactive Human Monoclonal Antibodies That Potently Neutralize Australian Bat Lyssavirus Variants and Other Phylogroup 1 Lyssaviruses.
    Weir DL; Coggins SA; Vu BK; Coertse J; Yan L; Smith IL; Laing ED; Markotter W; Broder CC; Schaefer BC
    Viruses; 2021 Mar; 13(3):. PubMed ID: 33804519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alanine scanning of the rabies virus glycoprotein antigenic site III using recombinant rabies virus: implication for post-exposure treatment.
    Papaneri AB; Wirblich C; Marissen WE; Schnell MJ
    Vaccine; 2013 Dec; 31(49):5897-902. PubMed ID: 24120673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in the progress of monoclonal antibodies for rabies.
    Fan L; Zhang L; Li J; Zhu F
    Hum Vaccin Immunother; 2022 Dec; 18(1):2026713. PubMed ID: 35172707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient In Vitro and In Vivo Activity of Glyco-Engineered Plant-Produced Rabies Monoclonal Antibodies E559 and 62-71-3.
    Tsekoa TL; Lotter-Stark T; Buthelezi S; Chakauya E; Stoychev SH; Sabeta C; Shumba W; Phahladira B; Hume S; Morton J; Rupprecht CE; Steinkellner H; Pauly M; Zeitlin L; Whaley K; Chikwamba R
    PLoS One; 2016; 11(7):e0159313. PubMed ID: 27427976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in the development of monoclonal antibodies for rabies post exposure prophylaxis: A review of the current status of the clinical development pipeline.
    Sparrow E; Torvaldsen S; Newall AT; Wood JG; Sheikh M; Kieny MP; Abela-Ridder B
    Vaccine; 2019 Oct; 37 Suppl 1():A132-A139. PubMed ID: 30503659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of a Novel Human Rabies Monoclonal Antibody to Human Rabies Immunoglobulin for Postexposure Prophylaxis: A Phase 2/3, Randomized, Single-Blind, Noninferiority, Controlled Study.
    Gogtay NJ; Munshi R; Ashwath Narayana DH; Mahendra BJ; Kshirsagar V; Gunale B; Moore S; Cheslock P; Thaker S; Deshpande S; Karande S; Kumbhar D; Ravish HS; Harish BR; Pisal SS; Dhere R; Parulekar V; Blackwelder WC; Molrine DC; Kulkarni PS
    Clin Infect Dis; 2018 Jan; 66(3):387-395. PubMed ID: 29020321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and characterization of novel chimeric monoclonal antibodies for broad spectrum neutralization of rabies virus.
    Kim PK; Keum SJ; Osinubi MOV; Franka R; Shin JY; Park ST; Kim MS; Park MJ; Lee SY; Carson W; Greenberg L; Yu P; Tao X; Lihua W; Tang Q; Liang G; Shampur M; Rupprecht CE; Chang SJ
    PLoS One; 2017; 12(10):e0186380. PubMed ID: 29045436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilisation of Chimeric Lyssaviruses to Assess Vaccine Protection against Highly Divergent Lyssaviruses.
    Evans JS; Wu G; Selden D; Buczkowski H; Thorne L; Fooks AR; Banyard AC
    Viruses; 2018 Mar; 10(3):. PubMed ID: 29543715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.